Autoimmunity, Transplantation & Inflammatory Disease


The mission of the Autoimmunity, Transplantation & Inflammatory (ATI) disease area is to deliver drugs that safely and effectively improve the lives of individuals suffering from immune mediated and inflammatory diseases. To accomplish this mission, we focus our research on targeting the elements of the immune system that drive disease in a highly selective manner. This more specific therapeutic targeting is aiming at leaving intact other important functions of the immune system, thereby increasing the safety of our drugs. Because we realize that immune mediated and inflammatory diseases are complex and have features that are unique to humans, our research and exploratory clinical activities incorporate insights from clinical trials in patients as we innovate to discover more effective and safe medications.

From a disease indication standpoint, we concentrate our research efforts on autoimmune and inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, type I diabetes and systemic lupus erythematosus, as well as transplant rejection. Further, it is increasingly apparent that many diseases share immune pathways in their pathophysiology. Recognizing these previously unappreciated aspects of autoimmunity and inflammation in diverse diseases holds promise new opportunities for treatment of diseases beyond those listed above.


Selected Publications

Th17 cells, not IL-17+ γδ T cells, drive arthritic bone destruction in mice and humans. Pöllinger B, Junt T, Metzler B, Walker UA, Tyndall A, Allard C, Bay S, Keller R, Raulf F, Di Padova F, O'Reilly T, Horwood NJ, Patel DD, Littlewood-Evans A. J Immunol. 2011 Feb 15;186(4):2602-12. Epub 2011 Jan 7.

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P. Nat Rev Drug Discov. 2010 Nov;9(11):883-97. Epub 2010 Oct 29.

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH; Psoriasis Study Group, Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group, Rose K, Haider A, Di Padova F. Sci Transl Med. 2010 Oct 6;2(52):52ra72.

Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. Warncke M, Calzascia T, Coulot M, Balke N, Touil R, Kolbinger F, Heusser C. J Immunol. 2012 May 1;188(9):4405-11. Epub 2012 Mar 28.